Zirconium and Hafnium Complexes with Cycloheptane- or Cyclononane-Fused [OSSO]-Type Bis(phenolato) Ligands: Synthesis, Structure, and Highly Active 1‑Hexene Polymerization and Ring-Size Effects of Fused Cycloalkanes on the Activity

Zirconium and hafnium complexes bearing cycloheptane- or cyclononane-fused [OSSO]-type bis­(phenolato) ligands ([C7] and [C9], respectively) were prepared and subjected to the polymerization of 1-hexene as the precatalyst. The polymerizations produced poly­(1-hexene)­s with high activities and high isospecificity, where complexes bearing [C9] were more reactive than those bearing [C7]. Their activities were compared with those of the corresponding complexes bearing cyclohexane- and cyclooctane-fused ligands ([C6] and [C8], respectively), which we reported previously, to show the order of activity [C8] > [C9] > [C7] > [C6]. The ring-size effect on the activity was investigated with the help of DFT calculations on active and dormant cationic zirconium species, π complexes of the active species with propene, and transition states for propene insertion into the Zr–C­(<i>i</i>Bu) bond. The order of activity speculated from the activation energy, that is the energy difference between the π complex and the corresponding transition state, was [C8] > [C7] > [C9] ≈ [C6]. However, calculations on active and dormant cationic zirconium complexes including [B­(C₆F₅)₄]⁻ as the counteranion revealed that the active species are more stable than the dormant species by 9.1 kcal mol^–1 for [C8] followed by 7.4 kcal mol^–1 for [C9] and 3.1 kcal mol^–1 for [C7] and, in contrast, that the active species with [C6] is less stable by 1.0 kcal mol^–1 than the corresponding dormant species. Thus, the abundances of active species bearing [C6] and [C7] are reduced, which leads to the reversal of the order of [C7] and [C9] on the basis of activation energy to reproduce the order observed experimentally

Zirconium and Hafnium Complexes with Cycloheptane- or Cyclononane-Fused [OSSO]-Type Bis(phenolato) Ligands: Synthesis, Structure, and Highly Active 1‑Hexene Polymerization and Ring-Size Effects of Fused Cycloalkanes on the Activity

Zirconium and hafnium complexes bearing cycloheptane- or cyclononane-fused [OSSO]-type bis­(phenolato) ligands ([C7] and [C9], respectively) were prepared and subjected to the polymerization of 1-hexene as the precatalyst. The polymerizations produced poly­(1-hexene)­s with high activities and high isospecificity, where complexes bearing [C9] were more reactive than those bearing [C7]. Their activities were compared with those of the corresponding complexes bearing cyclohexane- and cyclooctane-fused ligands ([C6] and [C8], respectively), which we reported previously, to show the order of activity [C8] > [C9] > [C7] > [C6]. The ring-size effect on the activity was investigated with the help of DFT calculations on active and dormant cationic zirconium species, π complexes of the active species with propene, and transition states for propene insertion into the Zr–C­(<i>i</i>Bu) bond. The order of activity speculated from the activation energy, that is the energy difference between the π complex and the corresponding transition state, was [C8] > [C7] > [C9] ≈ [C6]. However, calculations on active and dormant cationic zirconium complexes including [B­(C₆F₅)₄]⁻ as the counteranion revealed that the active species are more stable than the dormant species by 9.1 kcal mol^–1 for [C8] followed by 7.4 kcal mol^–1 for [C9] and 3.1 kcal mol^–1 for [C7] and, in contrast, that the active species with [C6] is less stable by 1.0 kcal mol^–1 than the corresponding dormant species. Thus, the abundances of active species bearing [C6] and [C7] are reduced, which leads to the reversal of the order of [C7] and [C9] on the basis of activation energy to reproduce the order observed experimentally

DNA Methyltransferase Inhibitor Zebularine Inhibits Human Hepatic Carcinoma Cells Proliferation and Induces Apoptosis

<div><p>Hepatocellular carcinoma is one of the most common cancers worldwide. During tumorigenesis, tumor suppressor and cancer-related genes are commonly silenced by aberrant DNA methylation in their promoter regions. Zebularine (1-(β-_D-ribofuranosyl)-1,2-dihydropyrimidin-2-one) acts as an inhibitor of DNA methylation and exhibits chemical stability and minimal cytotoxicity both <em>in vitro</em> and <em>in vivo</em>. In this study, we explore the effect and possible mechanism of action of zebularine on hepatocellular carcinoma cell line HepG2. We demonstrate that zebularine exhibits antitumor activity on HepG2 cells by inhibiting cell proliferation and inducing apoptosis, however, it has little effect on DNA methylation in HepG2 cells. On the other hand, zebularine treatment downregulated CDK2 and the phosphorylation of retinoblastoma protein (Rb), and upregulated p21^WAF/CIP1 and p53. We also found that zebularine treatment upregulated the phosphorylation of p44/42 mitogen-activated protein kinase (MAPK). These results suggest that the p44/42 MAPK pathway plays a role in zebularine-induced cell-cycle arrest by regulating the activity of p21^WAF/CIP1 and Rb. Furthermore, although the proapoptotic protein Bax levels were not affected, the antiapoptotic protein Bcl-2 level was downregulated with zebularine treatment. In addition, the data in the present study indicate that inhibition of the double-stranded RNA-dependent protein kinase (PKR) is involved in inducing apoptosis with zebularine. These results suggest a novel mechanism of zebularine-induced cell growth arrest and apoptosis via a DNA methylation-independent pathway in hepatocellular carcinoma.</p> </div

Effect of zebularine on the DNMTs expression and DNA methylation in HepG2 cells.

<p>(A) The protein level of DNMT1, DNMT3a, and DNMT3b after zebularine treatment for 72 h at different concentrations. After treatment, the cells were harvested and western blot analysis was performed to detect the protein level of DNMT1, DNMT3a, and DNMT3b. GAPDH was used as a loading control. Data are the means ± SEM of results from at least three independent experiments. *<i>p</i><0.05, compared to 0 μM. (B) Scatter plot of the average beta values at 485,415 CpG sites for zebularine-treated (y-axis) and control (x-axis) HepG2 cells (n = 3 for each group). Dots for CpG sites whose delta-beta value is >0.1 or <−0.1 are shown in green (35 [0.0072%] hypermethylated and 162 [0.033%] hypomethylated CpG sites).</p

The effect of zebularine on HepG2 cell viability.

<p>HepG2 cells were treated with zebularine at indicated concentrations for 72 h (A) and 24 h (B). Cell growth was measured by WST assay. (C) HepG2 cells were treated with zebularine at indicated concentrations for 24 h. Uptake of BrdU was measured by ELISA. (D) HepG2 cells were treated with zebularine at indicated concentrations for 72 h. Apoptosis was measured by TUNEL assay. Data are the means ± SEM of results from at least three independent experiments. *<i>p</i><0.05, compared to 0 μM.</p

Effects of zebularine on the protein expression of cell-cycle regulator.

<p>The protein level of CDK2, p-Rb, and Rb after zebularine treatment for 24 h at different concentrations. After treatment, the cells were harvested and western blot analysis was performed to detect the protein level of CDK2, p-Rb, and Rb. GAPDH was used as a loading control. Data are the means ± SEM of results from at least three independent experiments. *<i>p</i><0.05, compared to 0 μM.</p

Effects of zebularine on phosphorylation of PKR.

<p>(A) The phosphorylation and expression of PKR after zebularine treatment for 72 h at different concentrations. After treatment, the cells were harvested and western blot analysis was performed to detect the phosphorylated and total PKR protein level. GAPDH was used as a loading control. *<i>p</i><0.05, compared to 0 μM. (B) Effect of the overexpression of PKR in zebularine-induced cell death. The forward transfection of the empty vector (Halo Tag control vector) as the control or the plasmid-containing PKR cDNA sequence (pFN21A-hPKR) was performed, and the cells were then treated with different concentrations of zebularine for 72 h. *<i>p</i><0.05, compared to control. Data are the means ± SEM of results from at least three independent experiments.</p

The effect of zebularine on apoptosis-related proteins.

<p>HepG2 cells were treated with zebularine at indicated concentrations for 72 h. (A) Caspase-3/7, -8, and -9 activities were determined using Caspase-Glo Assays. The data are expressed as fold-increase relative to the respective untreated samples (RLU/60 min/μg protein). (B) The protein level of Bax and Bcl-2 after zebularine treatment for 72 h at different concentrations. After treatment, the cells were harvested and western blot analysis was performed to detect the protein level of Bax and Bcl-2. GAPDH was used as a loading control. Data are the means ± SEM of results from at least three independent experiments. *<i>p</i><0.05, compared to 0 μM.</p

Effects of zebularine on the protein expression of p21^WAF/CIP1 and p53.

<p>The expression of p21^WAF/CIP1 and p53 after zebularine treatment for 24 h at different concentrations. After treatment, the cells were harvested and western blot analysis was performed to detect the protein level of p21^WAF/CIP1 and p53. GAPDH was used as a loading control. Data are the means ± SEM of results from at least three independent experiments. *<i>p</i><0.05, compared to 0 μM.</p

Effects of zebularine on phosphorylation of p44/42 MAPK.

<p>The phosphorylation and expression of p44/42 MAPK after zebularine treatment for 24 h at different concentrations. After treatment, the cells were harvested and western blot analysis was performed to detect the phosphorylated and total p44/42 MAPK protein level. GAPDH was used as a loading control. Data are the means ± SEM of results from at least three independent experiments. *<i>p</i><0.05, compared to 0 μM.</p